Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition

This article was originally published in PharmAsia News

Executive Summary

In a move that will bolster its position in oncology, Eisai will buy MGI Pharma in an all-cash deal valued at $3.9 billion, the firms announced Dec. 10

Related Content

Astellas Looks Up In 2010; Eisai Draws Growth From Domestic And Chinese Markets: Japanese Pharma Earnings Roundup (Part 1 Of 2)
Eisai Threatens To End Pfizer Alliance On Aricept Following Wyeth Acquisition
Astellas Pharma Branches Out In U.S., Offers Career-building Workshops To Employees
Eisai Raises U.S. Oncology Business Weight With MGI Pharma Acquisition
U.S. FDA Approves Eisai Oral Aloxi For Preventing CINV
Eisai, Takeda Report Losses Due to Acquisitions; Daiichi Sankyo Reports Earnings Lower Because Of NHI Drug Pricing
U.S. FDA Rejects Eisai’s Aquavan Injection
U.S. FDA Sets Advisory Date For MGI/Eisai's Aquavan
China And India Next Targets For Eisai’s Global Plan 
Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts